@article{3078906,
    title = "Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis (Digestive Diseases and Sciences, (2018), 63, 12, (3487-3497), 10.1007/s10620-018-5251-9)",
    author = "Ahn, S.H. and Marcellin, P. and Ma, X. and Caruntu, F.A. and Tak, W.Y. and Elkhashab, M. and Chuang, W.-L. and Tabak, F. and Mehta, R. and Petersen, J. and Guyer, W. and Jump, B. and Chan, A. and Subramanian, M. and Crans, G. and Fung, S. and Buti, M. and Gaeta, G.B. and Hui, A.J. and Papatheodoridis, G. and Flisiak, R. and Chan, H.L.Y.",
    journal = "Digestive Diseases and Sciences",
    year = "2019",
    volume = "64",
    number = "1",
    pages = "285-286",
    publisher = "Springer New York LLC",
    issn = "0163-2116, 1573-2568",
    doi = "10.1007/s10620-018-5294-y",
    keywords = "erratum;  Erratum;  error",
    abstract = "The original version of this article unfortunately contained affiliation and textual errors. This has been corrected with this erratum. Affiliation of eleventh author was incorrectly assigned. Dr. William Guyer is affiliated with Gilead Sciences Inc, Foster City, CA, USA. In Results section, Safety Profile subsection, the sentence, ‘Rates of serious adverse events were 11%, 10%, 7%, and 10% in groups A, B, C, and D, respectively, and 6%, 3%, and 5% in groups A, B, and D, respectively, among those patients who were treated with TDF’ should read as below: Rates of serious adverse events were 11%, 10%, 7%, and 10% in groups A, B, C, and D, respectively, and 6%, 3%, and 5% in groups A, B, and D, respectively, among those patients who were retreated with TDF. In Table 2, header ‘Mean HBV DNA change from baseline, log10 IU/mL (SD)’ row 3 is missing ‘B’ in genotype. Revised version of the Table 2 is given below. (Table presented.) © 2018, The Author(s)."
}